Mandate

Vinge has advised the lead investor ARCH Venture Partners in Moleculent’s $26 million Series A financing

June 19, 2024

Moleculent AB, a company pioneering technology to study the communication between cells in human tissue, has closed its oversubscribed $26 million Series A financing. The round was led by ARCH Venture Partners and co-led by Eir Ventures with participation from the company’s existing investors.

ARCH Venture Partners creates and invests in groundbreaking life science and technology companies. The firm is a recognized leader in commercializing technologies developed at academic institutions, corporate research groups and national laboratories.

The Vinge team primarily consisted of Johan Larsson, Maria Dahlin Kolvik, Stojan Arnerstål, David Olander, Johan Gavelin, Olof Löfvenberg and Alice Göransson.

Related

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026

Vinge advises Studentbostäder i Norden AB (publ) in connection with its issuance of bonds in an amount of SEK 500 million and its early redemption of outstanding bonds

Vinge has advised Studentbostäder i Norden AB (publ) in connection with its issuance of senior unsecured bonds in an amount of SEK 500 million (within a framework of SEK 750 million) and in parallel with the company's voluntary early redemption of previously issued bonds.
March 12, 2026